GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (STU:1C0) » Definitions » Inventory-to-Revenue

Celyad Oncology (STU:1C0) Inventory-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Celyad Oncology's Average Total Inventories for the quarter that ended in Jun. 2023 was €0.00 Mil. Celyad Oncology's Revenue for the three months ended in Jun. 2023 was €0.00 Mil.

Celyad Oncology's Inventory-to-Revenue for the quarter that ended in Jun. 2023 stayed the same from Dec. 2022 (0.00) to Dec. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Celyad Oncology Inventory-to-Revenue Historical Data

The historical data trend for Celyad Oncology's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Inventory-to-Revenue Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Celyad Oncology's Inventory-to-Revenue

For the Biotechnology subindustry, Celyad Oncology's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Inventory-to-Revenue falls into.



Celyad Oncology Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Celyad Oncology's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Inventory-to-Revenue (A: Dec. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2021 ) + Total Inventories (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

Celyad Oncology's Inventory-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue (Q: Jun. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2022 ) + Total Inventories (Q: Jun. 2023 )) / count ) / Revenue (Q: Jun. 2023 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celyad Oncology  (STU:1C0) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Celyad Oncology's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2023 )/Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=0/0*365 / 4
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Celyad Oncology's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2023 ) / Average Total Inventories (Q: Jun. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celyad Oncology Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (STU:1C0) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (STU:1C0) Headlines

No Headlines